Cytoprotectants
Links shared publicly online about this topic
Targeting The Cytoprotective Chaperone, Clusterin, For Treatment Of Advanced Cancer
medicalnewstoday.com — “UroToday.com - In the February 15, 2010 edition of Clinical Cancer Research, the group of Dr. Martin Gleave from the University of British Columbia reports on the molecular chaperones Clust” View full resource at medicalnewstoday.com
Most Recently Shared on April 24, 2010 at 12:05 pm By:
Targeting The Cytoprotective Chaperone, Clusterin, For Treatment Of Advanced Cancer http://mnt.to/3BHC #healthnews
Induction Of Clusterin By AKT--Role In Cytoprotection Against Docetaxel In Prostate Tumor Cells
medicalnewstoday.com — “In the online edition of Molecular Cancer Therapeutics, Dr. Bin Zhong and associates report a link between the signal transduction protein AKT and the androgen receptor chaperone protein cluster” View full resource at medicalnewstoday.com
Most Recently Shared on August 11, 2010 at 11:39 am By:
Induction Of Clusterin By AKT--Role In Cytoprotection Against Docetaxel In Prostate Tumor Cells http://ow.ly/18wzSq
Nrf2 establishes a glutathione-mediated gradient of UVB cytoprotection in the epidermis " Genes & Development
genesdev.cshlp.org — “Nrf2 establishes a glutathione-mediated gradient of UVB cytoprotection in the epidermis " Genes & Development” View full resource at genesdev.cshlp.org
Most Recently Shared on May 18, 2010 at 1:37 am By:
Nrf2 establishes a glutathione-mediated gradient of UVB cytoprotection in the epidermis [Research Papers]: Ultravi... http://bit.ly/c1b80x
Bactericidal effect of plaunotol, a cytoprotective antiulcer agent, against Helicobacter pylori -- Koga et al. 38 (3): 387 -- Journal of Antimicrobial Chemotherapy
jac.oxfordjournals.org — “Bactericidal effect of plaunotol, a cytoprotective antiulcer agent, against Helicobacter pylori -- Koga et al. 38 (3): 387 -- Journal of Antimicrobial Chemotherapy” View full resource at jac.oxfordjournals.org
Most Recently Shared on August 4, 2009 at 7:49 pm By:
M Auron MD Doctor, Pediatrician, Internist, and Physician
Emerging therapies for H. pylori - http://bit.ly/v38ZO - wow! what is plaunotol? - http://bit.ly/7P89n
Pharmacological characterization of the cytoprotective effects of polyunsaturated fatty acids in insulin-secreting BRIN-BD11 cells - Dhayal - 2011 - British Journal of Pharmacology - Wiley Online Library
onlinelibrary.wiley.com — “Pharmacological characterization of the cytoprotective effects of polyunsaturated fatty acids in insulin-secreting BRIN-BD11 cells - Dhayal - 2011 - British Journal of Pharmacology - Wiley Online Library” View full resource at onlinelibrary.wiley.com
Most Recently Shared on February 23, 2011 at 4:54 am By:
Pharmacological characterization of the cytoprotective effects of polyunsaturated fatty acids in insulinâ€*secre... http://bit.ly/fSGBVY
Pharmacological characterization of the cytoprotective effects of polyunsaturated fatty acids in insulin-secreting BRIN-BD11 cells - Dhayal - 2011 - British Journal of Pharmacology - Wiley Online Library
onlinelibrary.wiley.com — “Pharmacological characterization of the cytoprotective effects of polyunsaturated fatty acids in insulin-secreting BRIN-BD11 cells - Dhayal - 2011 - British Journal of Pharmacology - Wiley Online Library” View full resource at onlinelibrary.wiley.com
Most Recently Shared on February 22, 2011 at 7:56 pm By:
Drugs and Devices OW OW Health
Pharmacological characterization of the cytoprotective effects of polyunsaturated fatty acids in insulinâ€*secre... http://bit.ly/fSGBVY
Astaxanthin has cytoprotective properties against glycated protein/iron chelate-induced toxicity in human umbilical vein endothelial cells. | GreenMedInfo | Article | Natural Medicine | Alternative Medicine | Integrative Medicine
greenmedinfo.com — “This article on GreenMedInfo.com concerns - Cytoprotective role of astaxanthin against glycated protein/iron chelate-induced toxicity in human umbilical vein endothelial cells.” View full resource at greenmedinfo.com
Most Recently Shared on June 28, 2011 at 4:47 pm By:
Anesthesiology Article | Dantrolene
mdlinx.com — “The Cytoprotective Effects of Dantrolene: A Ryanodine Receptor Antagonist” View full resource at mdlinx.com
Most Recently Shared on December 20, 2010 at 5:09 am By:
Sandeep Pulim MD Physician, Doctor, and Health Communicator
Dr Huafeng Wei just commented on: The Cytoprotective Effects of Dantrolene: A Ryanodine Receptor Ant... http://bit.ly/ea5o5D #authorcmnt
Urology Article | Prostatic Neoplasms
mdlinx.com — “Treatment of Low-risk Prostate Cancer with Radical Hypofractionated Accelerated Radiotherapy with Cytoprotection (HypoARC): An Interim Analysis of Toxicity and Efficacy” View full resource at mdlinx.com
Most Recently Shared on May 31, 2011 at 8:03 pm By:
Sandeep Pulim MD Physician, Doctor, and Health Communicator
Treatment of Low-risk Prostate Cancer with Radical Hypofractionated Accelerated Radiotherapy with Cytop... http://bit.ly/lSRb9q #urology
The cancer 'TRAP'
physorg.com — “Current research suggests that TNF-receptor associated protein-1 (TRAP-1) may prevent cancer cell death. The related report by Leav et al, 'Cytoprotective Mitochondrial Chaperone TRAP-1 as a Novel Molecular Target in Localized and Metastatic Prostate Cancer,' appears in the January 2010 issue of the ...” View full resource at physorg.com
Most Recently Shared on December 29, 2009 at 10:59 pm By:
The cancer 'TRAP' http://bit.ly/8aYGOX
TRAP-1 may prevent cancer cell death, current research suggests
news-medical.net — “Current research suggests that TNF-receptor associated protein-1 (TRAP-1) may prevent cancer cell death. The related report by Leav et al, "Cytoprotective Mitochondrial Chaperone TRAP-1 as a Novel Molecular Target in Localized and Metastatic Prostate Cancer," appears in the January 2010 issue of the American Journal of Pathology.” View full resource at news-medical.net
Most Recently Shared on December 30, 2009 at 7:28 am By:
Prostate Cancer: TRAP-1 may prevent cancer cell death, current research suggests: Current research suggests that TN... http://bit.ly/8SHnsT
Trophos awarded US patent covering use of novel cardioprotective compound
news-medical.net — “Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos’ TRO40303 to reduce the cardiac reperfusion injury that contributes sign” View full resource at news-medical.net
Most Recently Shared on August 23, 2011 at 8:52 pm By:
Trophos awarded US patent covering use of novel cardioprotective compound: Trophos SA a clinical stage pharmaceu... http://t.co/UiqoUjH
News
orphazyme.com — “The company develops innovative therapies for the treatment of lysosomal storage diseases. At Orphazyme our mission is to develop paradigm changing medicine to improve the quality of life of affected patients and their families. The company was founded in June 2009. Orphazyme is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja J??ttela and Thomas Kirkegaard Jensen. Their pioneering work on the cytoprotective properties of human heat shock pro” View full resource at orphazyme.com
Most Recently Shared on September 7, 2011 at 1:09 pm By:
John Carroll Health Communicator
Orphazyme raises 14m euros for lysosomal storage disorders. http://t.co/7kaNpru
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
MNT Health News
Featured health news published by Medical News Today and chosen by the editorial team.
-
Health Feed
Heath News & Information
-
Genetics OW
Organizing genetics resources shared by health experts, advocates, and organizations into WisdomCards.
Advertisement
